| 11.04 -0.32 (-2.82%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.59 | 1-year : | 14.31 |
| Resists | First : | 11.63 | Second : | 12.26 |
| Pivot price | 11.24 |
|||
| Supports | First : | 10.63 | Second : | 8.84 |
| MAs | MA(5) : | 11.35 |
MA(20) : | 11.3 |
| MA(100) : | 10.95  |
MA(250) : | 13.41 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 44.3 |
D(3) : | 48.7 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 22.54 | Low : | 9.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KROS ] has closed above bottom band by 28.2%. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.5 - 11.56 | 11.56 - 11.62 |
| Low: | 10.84 - 10.92 | 10.92 - 10.98 |
| Close: | 10.92 - 11.04 | 11.04 - 11.14 |
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Sun, 01 Nov 2026
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tue, 27 Oct 2026
BlackRock reports a Keros Therapeutics (KROS) stake with sole voting power over 1.58M shares. - Stock Titan
Mon, 26 Oct 2026
Weekly Recap: Milestone payment and Phase II rinvatercept DMD trial - TradingView
Sat, 24 Oct 2026
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Rated "Hold" by Sell-Side Brokerages - MarketBeat
Thu, 22 Oct 2026
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage - TradingView
Tue, 29 Sep 2026
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 95.1 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 1,170 (K) |
| EPS | -3.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.22 |
| Profit Margin | 0 % |
| Operating Margin | -655.9 % |
| Return on Assets (ttm) | -11.8 % |
| Return on Equity (ttm) | -17.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.95 |
| Sales Per Share | 0.75 |
| EBITDA (p.s.) | -4.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -3.43 |
| PEG Ratio | 0 |
| Price to Book value | 0.83 |
| Price to Sales | 14.58 |
| Price to Cash Flow | -4.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|